BOSTON (TheStreet) -- Here are four ratings changes from TheStreet's stock model.4. The model downgraded jewelry seller Tiffany & Co. ( TIF) to "hold." The company is scheduled to report fiscal fourth-quarter results March 22. The numbers: Fiscal third-quarter profit inched down 1% to $43 million, or 34 cents a share, as revenue declined 2.9% to $598 million. The operating margin tightened from 13% to 12%. Tiffany & Co. holds $375 million of cash and $753 million of debt. The stock: Tiffany & Co. has soared 160% over the past year, outpacing major U.S. indices. The stock trades at a price-to-projected-earnings ratio of 19, a premium to peers. A PEG ratio of 1.9 indicates that shares are expensive based on growth expectations. A PEG ratio over 1 implies costly shares. 3. The model downgraded drug maker Warner Chilcott ( WCRX) to "hold." The numbers: Warner Chilcott's fourth-quarter loss narrowed to $9.5 million, or 4 cents a share, from $116 million, or 46 cents, a year earlier. Revenue nearly tripled to $686 million. Warner Chilcott's operating margin narrowed from 29% to 20%. Its balance sheet contains $539 million of cash and $3 billion of debt. The stock: Warner Chilcott has advanced 159% in the past 12 months, beating major benchmarks. The stock sells for a price-to-projected-earnings ratio of 8.1, a discount to the industry average of 11. The shares are expensive based on sales and cash flow.
2. The model upgraded managed-health-care company Humana ( HUM) to "buy."The numbers: Fourth-quarter profit soared 44% to $251 million, or $1.48 a share, as revenue inched up 1.9% to $7.6 billion. Humana's operating margin widened from 3.8% to 5.6%. The company holds $7.9 billion of cash and $2.1 billion of debt. The stock: Humana has surged 137% over the past year, outperforming U.S. indices. The stock is cheaper than those of health-care-services peers based on book value, sales and cash flow. It sells for a price-to-projected-earnings ratio of 8.5. 1. The model upgraded Eli Lilly ( LLY) to "buy." The numbers: Eli Lilly swung to a fourth-quarter profit of $915 million, or 83 cents a share, from a loss of $3.6 billion, or $3.31, a year earlier. Revenue increased 14% to $5.9 billion. Eli Lilly's operating margin contracted from 29% to 22%. Its balance sheet stores $4.5 billion of cash and $6.7 billion of debt. The stock: Eli Lilly has advanced 25% in the past year, lagging behind major benchmarks. The stock trades at a price-to-projected-earnings ratio of 7.1, a discount to competitors. Its PEG ratio of 0.4 reflects a 41% discount to the industry average. -- Reported by Jake Lynch in Boston.